PubMed

XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.

Muggia FM, Peters GJ, Landolph JR Jr.

Mol Cancer Ther. 2009 May 5. [Epub ahead of print]PMID: 19417150 [PubMed - as supplied by publisher]Related articles

Heidelberger symposium on the 50th anniversary of fluoropyrimidines.

Muggia FM.

Mol Cancer Ther. 2009 Apr 21. [Epub ahead of print] No abstract available. PMID: 19383852 [PubMed - as supplied by publisher]Related articles

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK.

Cancer. 2009 Apr 1;115(7):1395-403. Review.PMID: 19195045 [PubMed - indexed for MEDLINE]Related articles

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK.

Cancer. 2009 Mar 1;115(5):1028-35.PMID: 19156927 [PubMed - indexed for MEDLINE]Related articles

Brain metastases from choriocarcinoma: two patients illustrating key management issues.

Chen T, Ginosar D, Fink M, Chen A, Cieplinski W, Curtin J, Muggia FM.

J Chemother. 2008 Jun;20(3):405-7. No abstract available. PMID: 18606606 [PubMed - indexed for MEDLINE]Related articles

New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.

Muggia FM.

Semin Oncol. 2006 Dec;33(6 Suppl 12):S18-24. Review.PMID: 17223446 [PubMed - indexed for MEDLINE]Related articles

Completion rates of adjuvant chemotherapy for colon cancer: a historical perspective.

Grann VR, Muggia FM.

J Natl Cancer Inst. 2006 May 3;98(9):570-1. No abstract available. PMID: 16670377 [PubMed - indexed for MEDLINE]Related articlesFree article

Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.

Hamilton AL, Eder JP, Pavlick AC, Clark JW, Liebes L, Garcia-Carbonero R, Chachoua A, Ryan DP, Soma V, Farrell K, Kinchla N, Boyden J, Yee H, Zeleniuch-Jacquotte A, Wright J, Elliott P, Adams J, Muggia FM.

J Clin Oncol. 2005 Sep 1;23(25):6107-16.PMID: 16135477 [PubMed - indexed for MEDLINE]Related articles

Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM.

Clin Cancer Res. 2005 Aug 15;11(16):5912-9.PMID: 16115933 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase 1 clinical trials in oncology.

Muggia FM.

N Engl J Med. 2005 Jun 9;352(23):2451-3; author reply 2451-3. No abstract available. PMID: 15948269 [PubMed - indexed for MEDLINE]Related articles

Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 15):19-24. Review.PMID: 15726535 [PubMed - indexed for MEDLINE]Related articles

Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.

Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 14):17-24. Review.PMID: 15726530 [PubMed - indexed for MEDLINE]Related articles

Liposomal anthracycline treatment for ovarian cancer.

Markman M, Gordon AN, McGuire WP, Muggia FM.

Semin Oncol. 2004 Dec;31(6 Suppl 13):91-105. Review.PMID: 15717739 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. Review.PMID: 15717738 [PubMed - indexed for MEDLINE]Related articles

Platinums: extending their therapeutic spectrum.

Muggia FM, Fojo T.

J Chemother. 2004 Nov;16 Suppl 4:77-82. Review.PMID: 15688617 [PubMed - indexed for MEDLINE]Related articles

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.

Muggia FM, Blessing JA, Waggoner S, Berek JS, Monk BJ, Sorosky J, Pearl ML.

Gynecol Oncol. 2005 Jan;96(1):108-11.PMID: 15589588 [PubMed - indexed for MEDLINE]Related articles

'Retarded pharmaceuticals' assuming a clinical role.

Muggia FM.

Onkologie. 2004 Oct;27(5):437-8. No abstract available. PMID: 15585972 [PubMed - indexed for MEDLINE]Related articles

Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Muggia FM, Blessing JA, McGehee R, Monk BJ.

Gynecol Oncol. 2004 Aug;94(2):483-7.PMID: 15297192 [PubMed - indexed for MEDLINE]Related articles

Re: 'Radiation recall dermatitis induced by pegylated liposomal doxorubicin'.

Muggia FM.

Anticancer Drugs. 2004 Jan;15(1):35. No abstract available. PMID: 15090741 [PubMed - indexed for MEDLINE]Related articles

The emerging roles of screening and prevention in women's cancer.

Muggia FM.

Oncologist. 2004;9(2):228-31. No abstract available. PMID: 15047928 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Muggia FM, Blessing JA, Method M, Miller DS, Johnson GA, Lee RB, Menzin A; Gynecologic Oncology Group study.

Gynecol Oncol. 2004 Feb;92(2):639-43.PMID: 14766259 [PubMed - indexed for MEDLINE]Related articles

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM.

J Clin Oncol. 2004 Jan 1;22(1):120-6.PMID: 14701774 [PubMed - indexed for MEDLINE]Related articles

Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132.

Muggia FM.

Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:156-62.PMID: 14656273 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal therapy as consolidation for patients with ovarian cancer and negative reassessment after platinum-based chemotherapy.

Lu MJ, Sorich J, Hazarika M, Kim M, Del Priore G, Jacobs AJ, Chiang C, Liu PC, Fusco E, Curtin JP, Muggia FM.

Hematol Oncol Clin North Am. 2003 Aug;17(4):969-75. Review.PMID: 12959186 [PubMed - indexed for MEDLINE]Related articles

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions.

Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM.

Ann Oncol. 2003 Sep;14(9):1430-7.PMID: 12954584 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of sarcomas: thinking out-of-the-box.

Muggia FM, Pavlick A.

Cancer Invest. 2003 Apr;21(2):321-2. No abstract available. PMID: 12743996 [PubMed - indexed for MEDLINE]Related articles

Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.

Haigentz M Jr, Kim M, Sorich J, Lee J, Hochster H, Macapinlac M, Mirchandani D, Sewak S, Pavlick A, Volm M, Hamilton A, Muggia FM.

Anticancer Drugs. 2003 Apr;14(4):321-6.PMID: 12679737 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R.

Clin Cancer Res. 2003 Mar;9(3):1145-54.PMID: 12631620 [PubMed - indexed for MEDLINE]Related articlesFree article

Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies.

Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, Metselaar JM, Storm G, Chanan-Khan A, Liebes L, Muggia FM, Cohen R, Barenholz Y, Alving CR.

J Liposome Res. 2002 Feb-May;12(1-2):165-72.PMID: 12604051 [PubMed - indexed for MEDLINE]Related articles

A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.

Sewak S, Chachoua A, Hamilton A, Taneja S, Lee J, Utate M, Sorich J, Muggia FM.

Anticancer Drugs. 2003 Jan;14(1):67-72.PMID: 12544260 [PubMed - indexed for MEDLINE]Related articles

Boosting bioavailability to topotecan: what do we gain?

Muggia FM.

J Clin Oncol. 2003 Jan 1;21(1):177; author reply 177. No abstract available. PMID: 12506192 [PubMed - indexed for MEDLINE]Related articles

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.

Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J, Jiang JD, Muggia FM, Perez-Soler R.

Mol Cancer Ther. 2002 Aug;1(10):841-9.PMID: 12492117 [PubMed - indexed for MEDLINE]Related articlesFree article

Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study.

Hawes D, Liu PY, Muggia FM, Wilczynski S, Cote R, Felix J, Terada K, Belt RJ, Alberts DS.

Gynecol Oncol. 2002 Oct;87(1):17-23.PMID: 12468337 [PubMed - indexed for MEDLINE]Related articles

Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.

Muggia FM, Liebes L, Hazarika M, Wadler S, Hamilton A, Hornreich G, Sorich J, Chiang C, Newman E, Potmesil M, Hochster H.

Anticancer Drugs. 2002 Sep;13(8):819-25.PMID: 12394266 [PubMed - indexed for MEDLINE]Related articles

Endometrial carcinoma with cerebellar metastasis: a case report and review of the literature.

Sewak S, Muggia FM, Zagzag D.

J Neurooncol. 2002 Jun;58(2):137-40. Review.PMID: 12164685 [PubMed - indexed for MEDLINE]Related articles

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study.

Muggia FM, Blessing JA, Sorosky J, Reid GC.

J Clin Oncol. 2002 May 1;20(9):2360-4.PMID: 11981008 [PubMed - indexed for MEDLINE]Related articles

Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.

Hines BJ, Porges RF, Mittal K, Muggia FM, Curtin JP.

Gynecol Oncol. 2002 Apr;85(1):192-5.PMID: 11925144 [PubMed - indexed for MEDLINE]Related articles

Thoughts about September 11, 2001: civilization's resilience and tenacity.

Muggia FM.

Oncologist. 2002;7(1):87. No abstract available. PMID: 11854553 [PubMed - indexed for MEDLINE]Related articlesFree article

Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.

Garcia AA, Muggia FM, Spears CP, Jeffers S, Silberman H, Pujari M, Koda RT.

Anticancer Drugs. 2001 Jul;12(6):505-11.PMID: 11459996 [PubMed - indexed for MEDLINE]Related articles

Doxil-induced radiation recall: a cause for false-positive PET scan findings.

Hornreich G, Schloss C, Hoskins WJ, Muggia FM.

Gynecol Oncol. 2001 Mar;80(3):422-3. No abstract available. PMID: 11263948 [PubMed - indexed for MEDLINE]Related articles

Liposomal encapsulated anthracyclines: new therapeutic horizons.

Muggia FM.

Curr Oncol Rep. 2001 Mar;3(2):156-62. Review.PMID: 11177748 [PubMed - indexed for MEDLINE]Related articles

Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.

Fleming GF, Roth BJ, Baker SD, Sutton GP, Look KY, Muggia FM, Fracasso PM, McGuire WP 3rd.

Am J Clin Oncol. 2000 Dec;23(6):609-13.PMID: 11202808 [PubMed - indexed for MEDLINE]Related articles

Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome.

Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow CP, Burnett A, Muggia FM.

Cancer. 2001 Jan 1;91(1):90-100.PMID: 11148564 [PubMed - indexed for MEDLINE]Related articlesFree article

Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial.

Moinpour CM, Sawyers Triplett J, McKnight B, Lovato LC, Upchurch C, Leichman CG, Muggia FM, Tanaka L, James WA, Lennard M, Meyskens FL Jr.

Psychooncology. 2000 Jul-Aug;9(4):340-54.PMID: 10960931 [PubMed - indexed for MEDLINE]Related articles

Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.

Rosenthal MA, Gruber ML, Glass J, Nirenberg A, Finlay J, Hochster H, Muggia FM.

J Neurooncol. 2000 Mar;47(1):59-63.PMID: 10930101 [PubMed - indexed for MEDLINE]Related articles

Phase II study of liposomal doxorubicin in advanced gynecologic cancers.

Israel VP, Garcia AA, Roman L, Muderspach L, Burnett A, Jeffers S, Muggia FM.

Gynecol Oncol. 2000 Aug;78(2):143-7.PMID: 10926793 [PubMed - indexed for MEDLINE]Related articles

BRCA1 germline mutation presenting as an adenocarcinoma of unknown primary.

Klein P, Prolla G, Wallach R, Melamed J, Muggia FM.

Cancer J. 2000 May-Jun;6(3):188-90.PMID: 10882335 [PubMed - indexed for MEDLINE]Related articles

Maintenance chemotherapy in advanced ovarian cancer.

Piver MS, Muggia FM, Brady MF, Alvarez R.

J Clin Oncol. 2000 Apr;18(8):1803-5. No abstract available. PMID: 10764445 [PubMed - indexed for MEDLINE]Related articles

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM.

J Clin Oncol. 2000 Jan;18(1):106-15.PMID: 10623700 [PubMed - indexed for MEDLINE]Related articles

Cytoprotection: shelter from the storm.

Klein P, Muggia FM.

Oncologist. 1999;4(2):112-21. Review. No abstract available. PMID: 10337381 [PubMed - indexed for MEDLINE]Related articlesFree article